Objective-Mitochondrial depolarization aids platelet activation. Oxidized LDL (oxLDL) contains the medium length oxidatively truncated phospholipid hexadecyl azelaoyl-lysoPAF (HAz-LPAF) that disrupts mitochondrial function in nucleated cells, so oxLDL may augment platelet activation. Methods and Results-Flow cytometry showed intact oxLDL particles synergized with subthreshold amounts of soluble agonists to increase intracellular Ca 2ϩ , and initiate platelet aggregation and surface expression of activated gpIIb/IIIa and P-selectin. oxLDL also induced aggregation and increased intracellular Ca 2ϩ in FURA2-labeled cells by itself at low, although not higher, concentrations. HAz-LPAF, alone and in combination with substimulatory amounts of thrombin, rapidly increased cytoplasmic Ca 2ϩ and initiated aggregation. HAz-LPAF depolarized mitochondria in intact platelets, but this required concentrations beyond those that directly activated platelets. An unexpectedly large series of chemically pure truncated phospholipids generated by oxidative fragmentation of arachidonoyl-, docosahexaneoyl-, or linoleoyl alkyl phospholipids were platelet agonists. The PAF receptor, thought to effectively recognize only phospholipids with very short sn-2 residues, was essential for platelet activation because PAF receptor agonists blocked signaling by all these medium length phospholipids and oxLDL. Conclusions-Intact oxLDL particles activate platelets through the PAF receptor, and the PAF receptor responds to a far wider range of oxidized phospholipids in oxLDL than anticipated. (Arterioscler Thromb Vasc Biol. 2009;29:363-371.)
P latelet mitochondria maintain cellular energetics and viability, 1 but these organelles also affect platelet activation. Thrombin produces a rapid decrease in mitochondrial transmembrane potential, thereby increasing reactive oxygen specie formation and caspase 3 activation needed for maximal aggregation. 2 Combining maximal amounts of thrombin with collagen 3 or with activators of Bax, 4 a proapoptotic protein that physically targets mitochondria, generates a subpopulation of highly activated platelets, and blockade of the mitochondrial permeability transition pore suppresses this form of platelet activation. 5, 6 Oxidized low density lipoprotein (oxLDL) has a fundamental role in thrombotic disease and atherogenesis through activation of inflammatory cells that includes platelets, 7, 8 although the identity of the agonist(s) is unclear because oxLDL contains numerous bioactive compounds. 9 Oxidation of lipoprotein particles, either chemically or enzymatically, 10, 11 fragments phospholipids that contain polyunsaturated fatty acyl residues. One such oxidatively-truncated phospholipid, hexadecyl azelaoyl lysoPAF (HAz-LPAF), derived from oxidation of common linoleoyl residues, rapidly enters nucleated cells, traffics to mitochondria, and initiates the mitochondrial-dependent pathway to apoptotic cell death. 12 We determined whether oxidized LDL contains agents that disrupt platelet mitochondrial function, thereby increasing cellular responsiveness. We prepared pure samples of a series of fragmented alkyl glycerophosphocholines-acylated ly-soPAFs-found in oxidized LDL, and discovered that many of these stimulated platelets. However, these lipids, and intact oxLDL particles, were direct platelet agonists that did not require mitochondrial involvement. Instead, we find the range of PAF receptor ligands is larger than previously predicted and includes medium-length oxidatively truncated alkyl phospholipids found in oxLDL. We show low concentrations of intact oxLDL particles activate platelets only through their PAF receptor.
Materials and Methods
HAz-LPAF and PAF were from Avanti Polar Lipids; human LDL was oxidized with Cu 2 SO 4 as described 13 ; fractions from oxidized arachidonoyl-, linoleoyl-, and docosahexaneoyl-glycerophosphocholine and those prepared synthetically were as described 14 ; other materials are described in the supplemental materials (available online at http://atvb.ahajournals.org).
Cell Isolation
Protocols using human blood were approved by the Cleveland Clinic IRB committee. Platelets were isolated as described in the supplemental materials.
Flow Cytometry
Surface proteins were quantified as described (supplemental materials). Platelet mitochondrial transmembrane potential was examined in washed platelets (10 7 /mL) incubated (1 hour) with HAz-LPAF in serum-free RPMI, then with JC-1 (10 g/mL, 15 minutes) before they were washed twice with PBS and analyzed by 2 color flow cytometry.
Microscopy
Electron microscopy was performed as described in the supplemental materials. For fluorescent microscopy, washed platelets (500 L) were mixed with calcein-AM, treated with the specified reagents with mild shaking for 10 minutes at room temperature in a 4-well cover slip chamber before unattached cells were removed by washing.
Intracellular Ca 2؉ Measurement
Platelets (10 8 /mL) were incubated for 30 minutes with 1 mol/L FURA2-AM in PSG containing 1 g/mL prostaglandin E 1 , collected by centrifugation, and suspended in Hank's buffered salt solution. Fluorescence was continuously recorded at 25°C by alternating the excitation wavelength between 340 and 380 nm, and detecting the fluorescent emission at 510 nm with the bandwidth set at 2.5 nm for both emission and excitation.
Data Expression and Statistics
Experiments were performed at least 3 times with cells from different donors with representative experiments or meanϮSE from all experiments shown. Supplemental Tables I and II provide quantitative Ca 2ϩ data.
Results

Intact Oxidized LDL Particles Activate Platelets
Low amounts of intact oxLDL particles (5 g/mL) stimulated mobilization of platelet alpha granules as shown by surface expression of P-selectin ( Figure 1A ). Platelets failed to respond to a subthreshold concentration of thrombin (0.02 U/mL), but did so when a low concentration of oxLDL was included in the incubation ( Figure 1A and 1B ). This combined response was greater than that induced by oxLDL alone, so oxLDL and thrombin signaling interact to promote platelet activation. Intact oxLDL particles alone also stimulated the adhesive response of platelets, and in combination with thrombin again evoked a response that was more robust than by either single agonist ( Figure 1C ). OxLDL particles, like thrombin, enhanced spreading and scanning electron microscopy showed the combination of agonists produced highly spread clusters or aggregates of platelets (supplemental Figure I ).
oxLDL Priming and Activation Requires the PAF Receptor
Platelet activation by oxLDL was concentration dependent with concentrations from just under 1.5 g/mL up to 5 g/mL stimulating intracellular Ca 2ϩ flux, but then activation was significantly reduced as the concentration of oxLDL increased above 7 g/mL (supplemental Figure 2 ). Thrombin at 0.02 U/mL induced a modest increase in intracellular free Ca 2ϩ (Figure 2A ). oxLDL at 1.4 g/mL was a better agonist than this very low level of thrombin, and the combination of oxLDL and thrombin greatly increased the rapidity and extent of platelet activation compared to either agonist alone. Similarly, oxidized LDL augmented the Ca 2ϩ flux induced by ADP ( Figure 2B ) and collagen ( Figure 2C ). The inhibitory PAF receptor inverse agonist 15 WEB2086 abolished signaling by oxLDL, without altering the response to thrombin, ADP, or collagen ( Figure 2 ). WEB2086 also completely suppressed the cooperative effect of oxLDL on thrombin stimulated Ca 2ϩ 
Platelets Are Activated by the Truncated Phospholipid HAz-LPAF
Agonist-induced mitochondrial depolarization enhances platelet reactivity. 3, 6 The synthetic oxidatively truncated alkyl phospholipid HAz-LPAF depolarizes mitochondria of nucleated cells, 12 and it depolarized mitochondria in intact washed platelets ( Figure 3A ): Platelets exposed to 2.5 mol/L HAz-LPAF were not different from control cells, but-as with nucleated cells-5 and 10 mol/L HAz-LPAF increased the population with depolarized mitochondria. Physical isolation showed that cytochrome c escaped from its mitochondrial compartment in platelets exposed to the higher concentrations of HAz-LPAF ( Figure 3B ). Pure HAz-LPAF increased platelet cytoplasmic Ca 2ϩ levels in a concentration dependent way ( Figure 3C ), so this oxidatively truncated phospholipid is a direct platelet agonist. However, this Ca 2ϩ response was unrelated to the mitochondrial dysfunction because HAz-LPAF was Ϸ25-times more potent at stimulating platelets than it was in depolarizing their mitochondria (compare Figure 3A with Figure 3C ). Submicromolar concentrations of HAz-LPAF, like oxLDL, synergistically enhanced thrombin-induced increases in intracellular free Ca 2ϩ ( Figure 4A ). HAz-LPAF at 10 Ϫ7 mol/L also enhanced platelet activation by suboptimal amounts of ADP ( Figure 4B ) and collagen ( Figure 4C ). HAz-LPAF induced an immediate increase in intracellular Ca 2ϩ , in contrast to the delayed response to collagen, and it appears the response to the combination of HAz-LPAF and collagen is a direct summation of independent events.
The response of platelets to HAz-LPAF included changes in the conformation of surface gpIIb/IIIa to its active state recognized by PAC-1 antibody ( Figure 5A ). Again, the combination of HAz-LPAF and trace amounts of thrombin was more effective than either agonist alone. HAz-LPAF induced platelet aggregation, and this truncated phospholipid potentiated the effect of thrombin present at a concentration too low to induce aggregation by itself ( Figure 5B ). This synergistic effect of HAz-LPAF on substimulatory amounts of thrombin comes from PAF receptor signaling because CV3988, a PAF receptor analog and receptor antagonist, suppressed this costimulus dependent aggregation. Suppression of the synergistic activation was not complete because CV3988 has partial agonistic activity 16 (supplemental Figure  III) . Blockade of the PAF receptor by CV3988 also suppressed the ability of low concentrations of oxLDL to promote platelet aggregation by substimulatory amounts of thrombin ( Figure 5B ). Although CV3988 was only partially successful in reducing platelet activation and priming by HAz-LPAF and oxLDL, this stimulatory effect derived from PAF receptor activation because the more effective PAF receptor antagonists BN52021 and WEB2086 abolished HAz-GPC signaling and interaction with thrombin signaling (supplemental Figure IV) .
Numerous Phospholipid Truncation Products Activate Platelets
We determined whether HAz-LPAF was unique in its ability to stimulate platelets among the many oxidatively truncated phospholipids found in oxLDL, and so prepared pure samples of a series ( Figure 6A ) of phospholipids that are generated by the oxidative fragmentation of alkyl phospholipids with sn-2 docosahexenoyl, arachidonoyl, and linoleoyl residues. 14, 17 The backbone of this series of phospholipids is the lysoPAF (alkyl glycerophosphocholine) molecule that contains the sn-1 ether bond that is highly preferred by the PAF receptor. A large number of these structures at submicromolar concentrations induced a rapid increase in platelet cytoplasmic Ca 2ϩ level ( Figure 6B ). The effectiveness of these oxidatively truncated alkyl phospholipids varied significantly, and did so in a largely nonobvious way. For instance, the most active group of truncated phospholipids included those with the shortest sn-2 residues tested-4 carbon oxobutyryl and succinoyl residues-as expected, but also included 7 and 8 carbon long acidic ␣,␤ unsaturated keto residues. While there was no distinct pattern to platelet activation by these phospholipids, HAz-LPAF was a member of the most active group of the oxidatively truncated phospholipids. The PAF receptor antagonist WEB 2086 was completely effective in suppressing the response to HAz-LPAF, and this blockade and inactivation of the PAF receptor also completely suppressed platelet activation by every other oxidatively truncated alkyl phospholipid we tested ( Figure 6C ). The structurally unrelated PAF receptor antagonists BN52021 and WEB2086 were equally effective in suppressing platelet activation by HAz-LPAF (supplemental Figure IV) , so the PAF receptor has a far wider range of agonist selectivity than previously determined using diacyl phospholipid homologs with unmodified chain fatty acyl residues.
Discussion
Thrombin is present at low concentrations during the initiation phase of thrombosis 18 and low concentrations of oxLDL cooperated with substimulatory concentrations of thrombin-or collagen or ADP-to activate platelets. However, oxLDL particles by themselves also activated platelets because oxidative fragmentation of its pool of alkyl phospholipids generated PAF receptor agonists. Oxidation of polyunsaturated fatty acids in diacyl and alkyl phospholipids proceeds by identical mechanisms, but all the newly formed agonists arise from oxidation of the less abundant alkyl phospholipids. 13 There are two unusual aspects of platelet stimulation by the lipid agonists of oxidized LDL. First is that intact oxidized LDL particles were potent platelet agonists. We 13, 19 and others 20 -23 have shown that oxidation of LDL generates a host of agonists for platelets, monocytes, and polymorphonuclear leukocytes. Among these agonists are very low amounts of platelet-activating Factor (PAF) 24 and other very short-chained PAF analogs 19, 25 that are ligands for the PAF receptor that greatly prefers alkyl phosphatidylcholines. However, to assay and identify these agents the approach has been to extract, fractionate, and concentrate the biologically active species to remove the bulk of the inactive lipids that sequester the active lipids in inactive insoluble complexes. Here we find that either the relevant biologically active species are sufficiently soluble to allow them to partition between the lipoprotein particle and the platelet surface, or the sn-2 residue and the sn-1 ether bond of the newly formed oxidized alkyl phospholipids is available to PAF receptors on the platelet surface as found in the "lipid whisker" model for oxidized phospholipid interaction with CD36. 26 The second-and surprising-aspect of oxidized LDL activation of platelets is that the relevant receptor recognizing the lipids of oxLDL was the PAF receptor. Lysophosphatidic acid in oxLDL is described as the agonist in oxLDL that stimulates platelets via their LPA receptors, 27 although this stimulation occurred at higher concentrations of oxLDL than required for PAF receptor-dependent signaling. Platelet activation by very low concentrations of oxLDL was abolished by PAF receptor antagonists, establishing the primacy of the PAF receptor in platelet responses to microgram quantities of intact oxidized LDL particles. Lysophosphatidic acid is some 10-fold less effective 22 in stimulating platelets than oxidatively truncated phospholipids (supplemental Figure II) that act through the PAF receptor, and so stimulation of platelets at higher concentrations of oxLDL 22 may have a larger contribution by this lysolipid when PAF receptor signaling becomes ineffective at higher oxLDL concentrations.
The PAF receptor, which has critical roles in inflammation, thrombosis, and vascular disease, is expressed by all cells of the innate immune system. 28 -30 This receptor displays marked ligand selectivity, 28, 31 allowing it to detect infinitesimal amounts of PAF in a sea of membrane phospholipids and lysophosphatidylcholines. 32, 33 A central feature of this selectivity is recognition of the unique short acetyl sn-2 residue of PAF, accompanied by a similarly strong recognition of the sn-1 ether bond and the choline headgroup. A model 34 of PAF interaction with its receptor postulates a binding pocket that physically rejects longer sn-2 residues. This modeling, however, is based on synthetic phospholipids where the sn-2 residue is a straight short-chained fatty acyl molecule, and this understanding was established before a molecular definition of the plethora of oxidatively truncated phospholipids found in oxidized lipoprotein particles, 20 -23,35 apoptotic cells, 36 and platelet microparticles. 37 Oxidized alkyl phospholipids break the paradigm established with these short straight-chained fatty phospholipids and introduce a host of new structures with a variety of oxy functions and carbon skeletons that can productively interact with the PAF receptor.
Examination of the PAF-like activity of a series of oxidatively truncated alkyl phospholipids shows that a short sn-2 residue is not an absolute criterion for an effective PAF receptor ligand. This means that oxidative fragmentation of any polyunsaturated fatty acyl residue, whether docosahexaenoyl or arachidonoyl residues that yield shorter 4 and 5 carbon fragments or linoleoyl residues forming 9 carbon long fragments, can generate effective PAF receptor agonists. Thus, PAF receptor agonists now also include longer sn-2 acidic residues such as the 9 carbon long HAz-LPAF, and 7and an 8-carbon long keto acids (KHdiA-GLPAF and KOdiA-LPAF, respectively). Only a few of the oxidatively truncated phospholipids bearing an -terminal aldehyde function were agonists, excluding a role for protein adduction by Shiff base formation in platelet activation by aldehydic phospholipids.
The pattern of platelet activation through the PAF receptor by ether-containing phospholipids is distinct from the pattern of effective CD36 ligands. 38 This is epitomized by KODA-PC, the most efficient diacyl CD36 ligand, 20, 38 which failed to stimulate platelets ( Figure 6 ). Although CD36 stimulation by oxLDL requires several hundred micrograms of oxLDL, 39 CD36 could still bridge lower concentrations of oxidized LDL to platelets in a way that enhances platelet reactivity and promotes intravascular thrombosis. 20 Platelets in different environments are exposed to vastly different levels of oxLDL, from the low number of modified particles in the circulation 40 to the high levels sequestered in atherosclerotic lesions. OxLDL itself was a potent platelet agonist, but it also was synergistic with amounts of thrombin (0.02 U/mL) too low to be stimulatory by itself, so the PAF receptor ligands in oxLDL are positioned to promote events early in thrombosis. Additionally, OxLDL contains, at a minimum, various oxidatively modified phospholipids and cholesterols, isoprostanes and oxidized arachidonoyl residues, 41 lysolipids generated by PAF acetylhydrolase hydrolysis of the newly minted oxidized phospholipids, 42, 43 and lysophosphatidic acid. 9 As might be expected from this, the effect of oxLDL on inflammatory cells is complex, dependent on the particle concentration and extent and mode of oxidation. 9 We observed that intact oxLDL particles functioned as full direct platelet agonists at a few g/mL, and achieved a maximal response by Ϸ7 g/mL. This response then faded as the oxLDL concentration increased, suggesting the additional Figure 6 . Truncated phospholipids created by oxidation of common phospholipids activate platelets through the PAF receptor. A, Reaction scheme depicting pathways forming specific phospholipid oxidation products starting from acyl lysoPAFs (alkyl glycerophosphocholines) containing the common arachidonoyl (AA), docosahexaneoyl (DHA), or linoleoyl (LA) polyunsaturated fatty acyl residues. B, Platelet stimulation by oxidized phospholipids. Intracellular Ca 2ϩ as a function of time in platelets treated with 0.5 mol/L of the stated phospholipid. C, Effect of PAF receptor inhibition. Platelets were pretreated with 10 mol/L WEB2086, except for one sample of OB-LPAF that served as the positive control, before Ca 2ϩ levels were determined.
presence of a less potent antagonist(s). One lipid of oxLDL that can interfere with platelet function is lysophosphatidylcholine, 9, 44 but its role is enigmatic. Its actions are concentration dependent, either aiding or suppressing platelet function, and acts in receptor-dependent and independent ways. Other antiinflammatory agents present in oxLDL 45 may also participate in forming the bell-shaped action profile, while the variety of agonists-particularly lysophosphatidic acid 22 could produce the stimulation found at oxLDL higher concentrations.
Controversy exists 46 regarding whether the circulating enzyme PAF acetylhydrolase/lipoprotein-associated phospholipase A 2 that hydrolyzes PAF and oxidized phospholipids is antiinflammatory 29, 47, 48 or proinflammatory. 49 These opposing views depend on whether one regards the substrate PAF or its lysoPAF product as the primary bioactive entity of oxidized LDL. Here we find several oxidatively truncated phospholipids that were less effective agonists than the lysolipid product, so their hydrolysis would enhance platelet activation. Conversely for the larger number of oxidatively truncated phospholipids that were more effective than the corresponding lysolipid hydrolytic product, hydrolysis by PAF acetylhydrolase would decrease PAF receptor activity. Resolution of these disparate views based on substrate selectivity is problematic.
